Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Psychological traits may uncover why Alzheimer’s biology differs between patients

22

Jun 2026

Psychological traits may uncover why Alzheimer’s biology differs between patients

In 822 deceased older adults from ROS and MAP, researchers linked stable psychological traits to multi-omic molecular subtypes of Alzheimer’s dementia using postmortem brain tissue from the dorsolateral prefrontal cortex. Neuroticism and loneliness were associated with molecular progression, while purpose in life showed subtype-specific inverse associations, suggesting psychological traits may align with Alzheimer’s biology beyond conventional neuropathology.

Amazon land use patterns reveal where vector-borne diseases collide

22

Jun 2026

Amazon land use patterns reveal where vector-borne diseases collide

Researchers found that malaria-Chagas and dengue-ATL hotspots in the Brazilian Amazon aligned with distinct agrarian, socioeconomic, and environmental landscapes. The findings suggest that disease surveillance should account for land use, poverty, forest structure, mining, and local livelihoods rather than treating each infection in isolation.

Statins may trigger muscle side effects by activating inflammatory danger signals

22

Jun 2026

Statins may trigger muscle side effects by activating inflammatory danger signals

An experimental study in Science Advances shows that statins, primarily fluvastatin in these experiments, may promote low-level muscle myopathy by reducing isoprenoid-dependent protein prenylation rather than by cholesterol lowering. In primed muscle cells and mouse models, impaired YAP signaling, reduced glycolysis, NLRP3/caspase-1 activation, and nuclear FOXO accumulation increased atrogin-1, reduced protein synthesis, and weakened muscle function.

Scientists trace cardiac aging to a fading regulator in heart muscle cells

22

Jun 2026

Scientists trace cardiac aging to a fading regulator in heart muscle cells

Researchers mapped 442,239 single nuclei from nonfailing human hearts to chart how cardiac cells change from fetal development to older adulthood. The study identified PRDM16 as an age-declining cardiomyocyte regulator, with experimental evidence showing that restoring Prdm16 in aged mouse hearts improved systolic function and partly reversed aging-associated transcriptional patterns.

UCLA researcher receives grant for advanced osteosarcoma immunotherapy

22

Jun 2026

UCLA researcher receives grant for advanced osteosarcoma immunotherapy

Physician-scientist Theodore Scott Nowicki, MD, PhD, an assistant professor in the department of pediatrics hematology/oncology and microbiology, immunology, & molecular genetics at the David Geffen School of Medicine at UCLA, has been awarded the Hero Grant from MIB Agents, a nonprofit organization dedicated to improving outcomes for children and young adults with osteosarcoma.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.